Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer

(American Society for Radiation Oncology) Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news